The FDA-labeled contraindications for RhIG vary by manufacturer but include the following:

- A hemolytic reaction may result if given to Rh-positive patients; RhIG should be avoided in these individuals.

- Patients with a history of severe hypersensitivity or anaphylaxis to any human immune globulin product.

- Patients with preexisting hemolysis, autoimmune hemolytic anemia, or high risk for hemolysis.

- RhIG products may contain a small quantity of IgA and should be avoided in IgA deficientÂ individuals with antibodies against IgA.